For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
'Animal,' Episode 3: Manatees
'The Interview': Serena Williams’s Next Challenge? The Rest of Her Life.
How to Retire as Early as Humanly Possible
Inside Trump’s Search for a Vice President
The Criminal Conviction of Hunter Biden
Biden’s Hard-Line Effort to Close the Border
The Rise and Fall of Congestion Pricing in New York
'Animal,' Episode 2: Puffins
'The Interview': The Darker Side of Julia Louis-Dreyfus
Real Teenagers, Fake Nudes: The Rise of Deepfakes in American Schools
The Fight Over the Next Pandemic
Biden’s Push to End the War in Gaza
A Conversation With President Zelensky
How Trump’s Conviction Could Reshape the Election
Introducing ‘Animal’: Walnut
'The Interview': Richard Linklater Sees the Killer Inside Us All
Guilty
The Government Takes On Ticketmaster
The Closing Arguments in the Trump Trial
The Alitos and Their Flags
Create your
podcast in
minutes
It is Free
Up First from NPR
The Ezra Klein Show
Matter of Opinion
Economist Podcasts
The Headlines